173 related articles for article (PubMed ID: 27379361)
1. A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control.
Feng W; Gao C; Liu W; Ren H; Wang C; Ge K; Li S; Zhou G; Li H; Wang S; Jia G; Li Z; Zhang J
Chem Commun (Camb); 2016 Aug; 52(60):9434-7. PubMed ID: 27379361
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Activated Anticancer Prodrug for Bioimaging, Tracking Drug Release, and Anticancer Application.
Liu W; Liu H; Peng X; Zhou G; Liu D; Li S; Zhang J; Wang S
Bioconjug Chem; 2018 Oct; 29(10):3332-3343. PubMed ID: 30192132
[TBL] [Abstract][Full Text] [Related]
3. A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.
Liu P; Xu J; Yan D; Zhang P; Zeng F; Li B; Wu S
Chem Commun (Camb); 2015 Jun; 51(46):9567-70. PubMed ID: 25971544
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Peng X; Gao J; Yuan Y; Liu H; Lei W; Li S; Zhang J; Wang S
Bioconjug Chem; 2019 Nov; 30(11):2828-2843. PubMed ID: 31592652
[TBL] [Abstract][Full Text] [Related]
5. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
[TBL] [Abstract][Full Text] [Related]
6. A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy.
Yang Z; Lin H; Huang J; Li A; Sun C; Richmond J; Gao J
Chem Commun (Camb); 2019 Apr; 55(31):4546-4549. PubMed ID: 30924831
[TBL] [Abstract][Full Text] [Related]
7. Developing glutathione-activated catechol-type diphenylpolyenes as small molecule-based and mitochondria-targeted prooxidative anticancer theranostic prodrugs.
Bao XZ; Dai F; Wang Q; Jin XL; Zhou B
Free Radic Biol Med; 2019 Apr; 134():406-418. PubMed ID: 30707929
[TBL] [Abstract][Full Text] [Related]
8. A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.
Liu L; Liu F; Liu D; Yuan W; Zhang M; Wei P; Yi T
Angew Chem Int Ed Engl; 2022 Mar; 61(12):e202116807. PubMed ID: 35068033
[TBL] [Abstract][Full Text] [Related]
9. Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring.
Cao Y; Pan R; Xuan W; Wei Y; Liu K; Zhou J; Wang W
Org Biomol Chem; 2015 Jun; 13(24):6742-8. PubMed ID: 25997534
[TBL] [Abstract][Full Text] [Related]
10. Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance.
Song H; Li W; Qi R; Yan L; Jing X; Zheng M; Xiao H
Chem Commun (Camb); 2015 Jul; 51(57):11493-5. PubMed ID: 26094840
[TBL] [Abstract][Full Text] [Related]
11. Dual-target cancer theranostic for glutathione S-transferase and hypoxia-inducible factor-1α inhibition.
Li Z; Ding J; Chen C; Chang J; Huang B; Geng Z; Wang Z
Chem Commun (Camb); 2017 Nov; 53(92):12406-12409. PubMed ID: 29112209
[TBL] [Abstract][Full Text] [Related]
12. Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner.
Fujimoto K; Takematsu YK; Shigeno A; Furusawa M; Sakamoto T
Bioorg Med Chem Lett; 2014 Aug; 24(16):3736-8. PubMed ID: 25080163
[TBL] [Abstract][Full Text] [Related]
13. A light-activatable theranostic combination for ratiometric hypoxia imaging and oxygen-deprived drug activity enhancement.
Ge L; Tang Y; Wang C; Chen J; Mao H; Jiang X
Nat Commun; 2024 Jan; 15(1):153. PubMed ID: 38167737
[TBL] [Abstract][Full Text] [Related]
14. Small conjugate-based theranostic agents: an encouraging approach for cancer therapy.
Kumar R; Shin WS; Sunwoo K; Kim WY; Koo S; Bhuniya S; Kim JS
Chem Soc Rev; 2015 Oct; 44(19):6670-83. PubMed ID: 26118960
[TBL] [Abstract][Full Text] [Related]
15. Noncovalent Theranostic Prodrug for Hypoxia-Activated Drug Delivery and Real-Time Tracking.
Zhao XB; Gao K; Shi YP
Anal Chem; 2021 Nov; 93(45):15080-15087. PubMed ID: 34743509
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-Directed and Self-Immolative Theranostic Agent: Imaging and Treatment of Cancer and Bacterial Infections.
Karan S; Cho MY; Lee H; Kim HM; Park HS; Han EH; Sessler JL; Hong KS
J Med Chem; 2023 Oct; 66(20):14175-14187. PubMed ID: 37823731
[TBL] [Abstract][Full Text] [Related]
17. p-(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumors.
Kwon CH; Blanco DR; Baturay N
J Med Chem; 1992 May; 35(11):2137-9. PubMed ID: 1597864
[No Abstract] [Full Text] [Related]
18. Targeting and Treatment of Tumor Hypoxia by Newly Designed Prodrug Possessing High Permeability in Solid Tumors.
Ikeda Y; Hisano H; Nishikawa Y; Nagasaki Y
Mol Pharm; 2016 Jul; 13(7):2283-9. PubMed ID: 27187083
[TBL] [Abstract][Full Text] [Related]
19. Designing luminescent ruthenium prodrug for precise cancer therapy and rapid clinical diagnosis.
Zhao Z; Zhang X; Li CE; Chen T
Biomaterials; 2019 Feb; 192():579-589. PubMed ID: 30551086
[TBL] [Abstract][Full Text] [Related]
20. A dithiocarbamate-based H
Pan Q; Zhang B; Peng X; Wan S; Luo K; Gao W; Pu Y; He B
Chem Commun (Camb); 2019 Nov; 55(92):13896-13899. PubMed ID: 31675022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
